During the third quarter, Allspring Global Investments Holdings LLC increased its stake in Halozyme Therapeutics by 247.8%, acquiring an additional 20,033 shares to bring its total holdings to 28,117 shares valued at approximately $2.11 million. This follows significant activity in the second quarter, when DLD Asset Management LP initiated a new position worth $650.25 million and Arrowstreet Capital Limited Partnership boosted its position by 127.8% to 2.54 million shares. Los Angeles Capital Management LLC also expanded its stake by 951.8%, purchasing 881,094 shares for roughly $50.65 million. In total, institutional investors now control 97.79% of the company’s outstanding stock, signaling strong confidence from major asset managers in Halozyme’s growth prospects.

Insider transactions over the last quarter saw director Bernadette Connaughton and CEO Helen Torley reduce their holdings by 4.75% and 2.28%, respectively. Connaughton sold 2,000 shares in early January, while Torley divested 16,569 shares in December. Combined insider sales totaled 45,661 shares with a gross transaction value of around $3.14 million. Despite these reductions, insiders still retain meaningful positions—Connaughton holds 40,123 shares and Torley controls 708,719 shares—indicating continued alignment with long-term shareholder interests even as they monetize portions of their stakes.

Halozyme reported third-quarter earnings per share of $1.72, exceeding consensus estimates by $0.09, while revenues rose 22.1% year-over-year to $354.3 million against analyst projections of $339.2 million. The company’s net margin stood at 47.9% with a return on equity of 156.9%. Following these results, research firms adjusted their outlooks: Zacks Research moved from strong-buy to hold, Morgan Stanley reduced its target slightly while maintaining an overweight rating, Weiss Ratings upgraded from hold to buy, Leerink Partners shifted to market perform, and JPMorgan Chase raised its neutral price objective. Of the 15 analysts covering the company, eight recommend buy, six recommend hold and one recommends sell, yielding an average consensus of hold.

Halozyme’s core technology platform, ENHANZE®, leverages recombinant human hyaluronidase PH20 to facilitate subcutaneous administration of biologics, offering potential benefits in patient convenience and cost of care. The company has formed multiple collaboration agreements with leading pharmaceutical and biotech firms to integrate ENHANZE® across a range of therapeutic candidates, including oncology and immunology products slated for clinical milestones in the coming quarters. Management’s guidance anticipates continued double-digit revenue growth driven by royalty streams and service revenue as additional products transition into late-stage development or commercialization.